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Abstract 
Background 
 Thirty to fifty percent of cancer patients undergoing chemotherapy will experience 
chemotherapy induced nausea and or vomiting (CINV) despite the use of antiemetic prophylaxis 
Uncontrollable CINV can lead to complications that add extra stress to patients, increase in 
healthcare costs, and utilization of resources. CINV can lead to chemotherapy dose reductions, 
treatment delays, chemotherapy changes, or discontinuation of treatment. Guidelines exist to 
better prevent and treat CINV.  Evidence supports the use of guidelines to prevent CINV, 
however patients still suffer from CINV often due to a lack of guideline adherence.  
Objectives 
 The purpose of this project was to increase CINV guideline adherence by increasing 
knowledge of antiemetic guidelines utilizing an educational intervention for providers and nurses 
at an outpatient oncology office.  
Methods 
 A brief educational intervention on CINV and recommended NCCN guidelines was 
conducted with providers and nurse (n=6) at an oncology practice in Southwestern United States. 
An evaluation to assess change in knowledge was performed using a pre and post test format. 
Statistical analysis was performed using descriptive statistics, McNemar tests and Wicoxan 
Signed Rank Test. 
Findings 
 There was a significant effect on knowledge of NCCN antiemetic guidelines (Z=-1.89, 
p=0.059, mean 2.5) post intervention. There also was a significant impact on likelihood to use 
guidelines in practice (Z=-1.89, p=0.059, mean 2.5). Increasing awareness and likelihood to 
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follow recommended guidelines may improve CINV symptoms in patients undergoing 
chemotherapy and improve the treatment outcomes for these patients.  
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Chemotherapy Induced Nausea and Vomiting Guideline Adherence 
 One of the most distressing side effects of cancer treatment is chemotherapy induced 
nausea and vomiting (CINV). CINV is difficult to assess and treat because it is subjective and 
often underreported by patients and its impact is often under estimated by providers. 
Problem Statement 
 Chemotherapy induced nausea and vomiting adds extra stress to patients and causes an 
increase in healthcare costs and utilization of resources. CINV can lead to chemotherapy dose 
reductions, treatment delays, chemotherapy changes, or discontinuation of treatment. Van Lear, 
Desai, and Jatoi (2015) found 32% of oncologists surveyed needed to delay or dose reduce 
chemotherapy due to CINV. Guidelines exist to better prevent and treat CINV (American 
Society of Clinical Oncology [ASCO], 2017; National Comprehensive Cancer Network 
[NCCN], 2017).  Evidence supports the use of guidelines to prevent CINV, however patients still 
suffer CINV often due to a lack of guideline adherence (Caracuel, Munoz, Banos, & Ramirez, 
2015). 
Purpose and Rationale 
 Chemotherapy induced nausea and vomiting is one of the most distressing and severe 
side effects of chemotherapy for patients (Hernandez Torrez et al., 2015; Inoue et al., 2015). 
Uncontrolled CINV negatively impacts patients’ lives and can lead to decreased quality of life, 
dehydration, and poor treatment outcomes. There is an extensive body of evidence to guide 
providers in effectively preventing and managing CINV. The purpose of this project is to create 
more knowledge and awareness of these guidelines in an effort to increase their use in practice.  
Background and Significance 
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 The National Cancer Institute (NCI) (2016) estimates one million people are diagnosed 
with cancer each year and for many of these people chemotherapy is a treatment option. It is 
estimated 30-50% of patients undergoing chemotherapy experience CINV (Hu et al., 2016; 
Moradian & Howell, 2015). It is a major concern because if left uncontrolled it can lead to dose 
reductions, treatment delays, and unanticipated stoppage of treatments which can affect overall 
treatment outcomes. Improving treatment outcomes and improving supportive and palliative 
therapy are major initiatives of the NCI (National Cancer Institute [NCI], 2016).  
 CINV is a major area of concern for both patients and providers. Hernandez Torres et al. 
(2015) suggest many providers consider adequate treatment of CINV to be the absence of 
emesis. However, patients report nausea just as distressing as vomiting (Hernandez Torres et al., 
2015; Vidall et al., 2015). Patients have also suggested providers underestimated the impact 
nausea has on daily life (Vidall et al., 2015). Van Lear et al. (2015) found 88%-92% of providers 
felt they could adequately control CINV but 38% of providers admitted to delaying, stopping, or 
changing chemotherapy due to uncontrolled CINV. This gap in patient provider perception of the 
impact of CINV suggests room for improvement in understanding and managing symptoms.  
Treating CINV can be a difficult undertaking as there are many risk factors and multiple 
mechanisms of actions. CINV usually occurs in the first 5 days following chemotherapy 
administration and poorly controlled nausea and vomiting during this time can cause anticipatory 
nausea and vomiting in following cycles of chemotherapy (Hopkins &Donovan, 2014; NCCN, 
2017; Tegeja &Groning, 2016).   
 Another complexity in the management of CINV is the emetogenic potential of certain 
chemotherapies meaning the likelihood of a chemotherapy to cause nausea and vomiting. 
Different chemotherapies and regimens have different emetogenic potentials which creates the 
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need for varying medications to control CINV. Tageja and Groninger (2016) as well as Boccia 
(2013) indicate multiday regimens for IV chemotherapy and oral chemotherapy agents further 
add to the emetogenic potential of medications.  
 The different types of CINV, multiple mechanisms of action, individual risk factors and 
the different emetogenic potential of chemotherapeutic agents require a complex assessment and 
multipronged approach to successfully manage CINV. This complexity has led to the importance 
of guidelines for the management CINV. 
To help manage the effects of CINV, professional organizations have created guidelines 
to help providers to adequately prescribe the correct prophylaxis and treatment needed. Three 
main organizations – the Multinational Association for Supportive Care in Cancer/ European 
Society for Medical Oncology (MASCC/ESMO), ASCO, and NCCN have all issued guidelines 
for the management of CINV. These guidelines were based on research and evidence in 
antiemetic agents, as well as consensus of experts. The Oncology Nursing Society (ONS), the 
major certifying agency for chemotherapy administration, recommends the utilization of 
guidelines.  
 Despite the evidence and consensus behind the guidelines, there is a lack of adherence to 
guideline recommendations. Guideline adherence is the responsibility of providers and patients. 
Providers must be aware of guideline recommendations to prescribe and educate the patients. 
Gilmore et al. (2014) found patients were less likely to experience CINV when guidelines were 
followed. 
 Guideline nonadherence can take many shapes and forms such as prescribing incorrect 
classes of medications, not prescribing corticosteroids in the delayed phase, and the over dosing 
of some medications. All of the guidelines take into account the emetogenic potential of the 
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chemotherapy agents used. The emetogenic potential of chemotherapy agents are classified as 
highly emetogenic (HEC), moderately emetogenic (MEC), low emetogenic (LEC), and 
minimally emetogenic. Some providers are less likely to adhere to guidelines with LEC, mostly 
by over prescribing medications with LEC regimens (Franca et al., 2015; Vidall et al., 2015). 
Other studies have found that guideline nonadherence was due to the lack of prescribing 
corticosteroids during the delayed phase of CINV (Burmeister, Aebi, Studer, Fey, & Gautschi, 
(2012).  
Another aspect of guideline adherence is patient compliance with medications. Patients 
must comply with the guideline recommendations and take medications as prescribed to achieve 
optimal results. Patient compliance is easier to manage in the hospital setting as nurses are often 
administering medications, however this is difficult to control in the outpatient setting when the 
patient must take medications independently at home in the days following chemotherapy 
administration. Caracuel et al. (2015) found only 61% of patients were compliant with their oral 
antiemetics. In another survey, only 38% of patients remembered taking their antiemetics as 
instructed (Vidall et al., 2015). Reasons patients did not want to take medications included not 
wanting to taking medications when not feeling nauseous, not wanting to take any additional 
medications, and being afraid taking medications may lead to vomiting (Vidall et al., 2015).  
Educating both providers and patients may be a way to help improve guideline adherence and 
better control CINV.  
 In an oncology practice in the Southwestern United States, patients are usually given their 
chemotherapy education on a day prior to starting chemotherapy. On this day, the patient often 
receives all the information needed for their entire chemotherapy course, including information 
for managing CINV. This amount of information is overwhelming and often forgotten. There is 
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no system currently set up to track the incidence of CINV or dehydration related to CINV in this 
practice.  
 Providers will often follow some of the NCCN guideline recommendations to insure 
insurance approval; however, there are often inappropriate exceptions or omissions.  For 
example, patients receiving HEC will often be written for a prescription for an NK-1 receptor 
antagonist (NK-1RA), 5-HT3RA, and corticosteroids per NCCN guidelines. Some patients are 
not able to afford the high cost associated with the NK-1RA and often this gets removed from 
the treatment plan. NCCN also recommends the use of olanzapine, an atypical antipsychotic, and 
corticosteroids orally as antiemetic prophylaxis prior to HEC but this option is rarely utilized.  
 The severity of CINV experienced by patients and the lack of guideline adherence raise 
the following PICO question: In adults undergoing chemotherapy, how does guideline adherence 
compare to nonadherence affect CINV? 
Search Process 
 A search of the literature was done using 3 databases - CINHAL, PubMed, and the 
Cochrane library. Search terms included chemotherapy, antiemesis, nausea, vomiting, guidelines, 
protocols, adherence, and compliance. Variations of these terms were also searched. The results 
were limited to the last 5 years to make sure current evidence was being used. All of the studies 
considered needed to include the use of chemotherapy guidelines. The results were also limited 
to adults over the age of 18. Ancestry was also used during the literature search (Appendix A).  
Critical Appraisal and Synthesis 
 Following the literature search, 10 high quality studies were used for critical appraisal 
and analysis. Most of the studies were level three cohort studies but two of the studies were level 
2 randomized control trials (RCTs) according to the hierarchy of evidence (Melnyk &Fineout-
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Overholt, 2015). The eight other studies reviewed were observational studies, retrospective and 
prospective studies (Appendix B).  There was homogeneity as all the studies showed better 
CINV outcomes with guideline adherence as a result, but only one study looked at patient 
adherence to prescription medication (Caracuel, et al., 2015). The samples all included cancer 
patients undergoing chemotherapy. Three studies looked at breast cancer patients and one study 
looked at glioma patients. There was some heterogeneity in the guidelines. Some studies used a 
combination of guidelines and some used independent institutional protocols.  
The studies took place all over the world, Europe, Japan, Singapore, Canada, and the 
United States. Most of the studies followed international guidelines except for two studies which 
followed institutional guidelines.  The most common guideline used was MASCC/ESMO 
guideline (Appendix C).  
 The consensus of results from the critical analysis shows guideline adherence when 
prescribing antiemetics has better outcomes. Antiemetic guidelines are evidenced based and have 
been shown to decrease CINV incidence. Decreased incidence of CINV improves the overall 
treatment experience and treatment outcomes of patients. Improving guideline adherence in both 
patients and providers can reduce the overall incidence of CINV. Controlling CINV in early 
chemotherapy cycles also improves the rates of anticipatory CINV in following cycles.  
Guideline consistent prescribing leads to less office and emergency room visits for dehydration 
secondary to CINV, lowering health care costs. Ensuring guideline adherence can reduce health 
care costs and decrease the incidences of CINV.  
Conceptual/Theoretical Model and Evidence Based Practice Model 
 The theory of symptom management depicts the three main components, symptom 
experience, the components of symptoms management, and the outcome, as being interrelated 
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and affecting each other (Linder, 2010). The symptoms experience and symptom management 
strategies are encompassed in the outcomes (Appendix D). The symptom experience, CINV, 
includes the perception, evaluation, and response to symptoms; symptoms management 
strategies includes the providers who deliver care, what is being done to improve the symptoms, 
how much and when the intervention is being delivered (Linder, 2010).  The symptoms 
management strategy utilized for the intervention is CINV guideline adherence. The symptom 
may or may not be present but may be a threat to the individual’s overall outcome. Adherence 
also plays a role in maintaining the balance of wellbeing and has the power to disrupt the 
outcome. Adherence or nonadherence to symptom management strategies may cause a 
worsening of symptoms and put an individual at risk for poor outcomes (Linder, 2010).   
 The evidence based practice model that drove this project was the Ottawa Model for 
Research Use (OMRU) (Graham & Logan, 2004). This model is a dynamic and fluid model for 
evidenced based practice. OMRU identifies who is responsible for making change decisions and 
key stakeholders for change (Appendix E). After key individuals are assessed, it is important to 
clearly state and know the intervention being implemented. The next step is to identify potential 
barriers and potential adopters and facilitators to the change.  After implementation, evaluation 
of knowledge translation and situational assessment are important to monitor the change. 
Another key aspect of monitoring change is the evaluation of the change and the impact it has on 
key stakeholders. Due to the dynamic nature of this model, there is a constant evaluation, 
assessment and monitoring of change and adaptations needed (Graham & Logan, 2004). The 
dynamic nature of this model allows for post intervention changes, which may be important to 
any change. The fluid nature of the OMRU allows for constant adaptation and change during the 
implementation process and helps to aid with sustainability.   
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 Using OMRU, the practice environment was assessed first. The patient flow and 
education were noted, and key individuals were identified. Potential adopters were also 
identified, as were those who could be resistant to change. Also, the evidence was analyzed and 
synthesized during the initial stages. The evidence transfer strategy chosen was dissemination, 
and an evidence based educational intervention was the tool used to disseminate the evidence. 
Following the interview, the staff chose to adopt the change and outcomes were assessed for 
providers.  
Project Methods 
 Protections of human subjects was approved through the Institutional Review Board at 
Arizona State University.  Recruitment was done by a team member familiar with the practice. 
Participants were provided with information of the intervention, including risks and benefits; 
consent was implied by participation in the educational intervention. Providers and nurses were 
asked to participate in a brief educational intervention. A pretest and posttest assessment was 
conducted before and immediately after the intervention (Appendix F). Unique identification 
numbers were assigned to the participants to maintain confidentiality. Content validity for the pre 
and posttest was assessed by review by content experts. 
 The educational session on CINV was prepared for both providers and nurses in the 
office using the evidence gathered from the literature search. The educational session discussed 
the underlying pathophysiology of CINV and risk factors for CINV; the educational session also 
included the 2017 NCCN guideline recommendations for HEC and MEC, patient education for 
CINV, and information the MASCC Antiemesis Tool (MAT) for objective CINV assessment.  
 Patient education material was created utilizing NCCN guidelines, ONS 
recommendations, and evidence gathered during the literature search and given to the 
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participants as part of the intervention. The educational sheets where written using plain 
language and clearly listed steps for patients to take to manage their CINV at home. Also 
included in the educational material was a blank calendar week for the patient to list when they 
needed to take their home corticosteroids and information on how to manage breakthrough 
medications as needed.  Lastly, the patient education sheet listed who to call for questions or 
uncontrolled CINV. 
Outcomes and Impact 
 Data gathered through the pretest and posttest was analyzed utilizing SPSS (IBM Corp, 
2016) for statistical analysis. Demographic information was analyzed using descriptive statistics. 
The sample consisted of two doctors and four nurses who cared for patients undergoing 
chemotherapy (n=6). The years of oncology experience ranged from 3 years to 17 years with a 
mean of 9.08 years (SD= 5.43).  The level of education of the participants included associate’s 
degrees, bachelor’s degrees, and MDs.  
 Pretest and posttest data were compared using the McNemar test and Wilcoxan Signed 
Rank test. Due to the pre-existing knowledge level of the participants about CINV, the McNemar 
test indicated this intervention failed to change the knowledge level and there was no change in 
the knowledge of CINV when comparing the pretest and the posttest.  
 Participants were asked to rate their familiarity with NCCN guidelines for antiemesis on 
a scale of zero to five before and after the intervention. Using the Wilcoxan Signed Rank test and 
a 90% confidence interval (a=0.1), there was a significant change in familiarity of the guidelines 
(Z= -1.89, p=0.059).  Similar results were found when participants were asked to rate their 
likelihood to use the guidelines in practice (Z= -1.89, p=0.059). These results indicate the 
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING 13 
intervention was effective in increasing knowledge of the guidelines and increasing the 
likelihood the participants would use them in practice.  
Discussion 
 CINV is very distressing for many patients undergoing chemotherapy and is a side effect 
that most patients are concerned about. Recommended guidelines are consensus and evidence 
based, making them the standard of practice. The results for both familiarity of NCCN guidelines 
and likelihood to use these guidelines in practice showed significant change following the 
educational intervention (Z= -1.89, p=0.059). The significance of these results indicates the 
educational intervention was effective at increasing familiarity and awareness of the guidelines. 
Improving the awareness of the guidelines and the options offered for treating CINV may 
improve patient symptoms and outcomes if applied to practice. 
 The intervention also caused a significant result in participants’ likelihood to use 
guidelines in practice (Z= -1.89, p=0.059). Increasing awareness of the recommended guidelines 
may increase provider adherence when writing antiemetic prophylaxis. Properly medicating 
patients before chemotherapy will have a positive effect on overall treatment outcomes because 
there will be an expected decrease in the treatment changes, stoppages, and delays. It may also 
decrease the cost to the healthcare system in general as there will likely to be less costs for 
additional medications and hydration treatments.  
Strengths and Limitations 
  One of the biggest strengths was this project did increase providers knowledge of the 
guidelines and providers reported an increase in likelihood to utilize the guidelines in practice. 
Another strength of this project was that it gave providers resources to use in future practice. 
This helps to aid in the sustainability as it creates a simpler way for assessing and educating 
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patient on CINV. Participants were able to keep the patient education designed from current 
evidence and a copy of the MAT tool for assessing CINV. Another strength of this intervention 
was it worked with the current practice environment and strengthened it with the current 
evidence.  
 This intervention did have some weaknesses as well as strengths. The first limitation was 
the timeframe for the intervention. Due to the limited time to perform the intervention, the 
original plan needed to be changed and excluded implementing the MAT tool and performing 
chart audits for outcome measures addressing compliance with guidelines and assessing whether 
there was an improvement in the management of CINV. Also, all of the educational sessions 
were held in one day and one participant did not finish the post test, making it difficult to 
compare the data.  The condensed timeframe also did not allow for the measurement of long 
term outcomes associated with the educational intervention. 
 Another limitation was the small sample size (n=6). While the sample was a sample of 
convenience by including participants who were in the office on that day, the small sample size 
may have affected the validity of the results and limited the transferability of the intervention.  
Conclusion 
 The purpose of this project was to increase knowledge regarding CINV guideline 
recommendations in an effort to increase guideline adherence. The educational intervention was 
designed specifically for the practice environment in which the project took place, limiting its 
transferability. The timeframe was also a large limitation of this intervention. Despite its 
limitations, this intervention demonstrated a significant change on familiarity with NCCN 
recommended guidelines for CINV. Participants also indicated a significantly higher likelihood 
to use the guidelines in future practice. This project provided the practice with additional patient 
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education tools which may help to improve patient adherence to prescribed treatment for the 
management of CINV.
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PubMed Search Strategy
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model guided; Rx- Prescribing/prescription; std- Standard; VAS- visual analog scale; X2- Chi Squared 
 
22 
Appendix B 
Evaluation Table 
 
 
Citation Theory/ 
Conceptual 
Framework 
Design/ 
Method 
Sample/ 
Setting 
Major 
Variables 
& 
Definitions 
Measurement/ 
Instrumentation 
Data 
Analysis 
(stats 
used) 
Findings/ 
Results 
Level/Quality 
of Evidence; 
Decision for 
practice/ 
application to 
practice 
Aapro et al., 
(2012). The 
effect of 
guideline-
consistent 
antemetic 
therapy on 
chemotherapy-
induced nausea 
and vomiting. 
 
Physiological 
framework 
Prospective 
Observational 
Multicenter 
Study 
 
n=1128 
Pt initiating 
HEC or MEC 
 
C1=991 
C2=888 
C3=769 
 
Setting: 8 
European 
Countries, 
Infn clinic 
IV- GCP 
DV-GIP 
 
 
g/l: MASCC 
Daily Diary 
Rx information 
VAS 
 
Pearson X2 
 
Student t-
test 
 
Multivariate 
logistic 
regression 
Adh 
increased in 
MEC. 
g/l Rx 
higher in AP 
MEC or 
HEC. 
CR higher in 
GCP. 
Desired 
outcomes 
higher GCP. 
Lvl of Evidence:  
Lvl 3 
 
 
Decision for 
Practice: GCP 
improves CINV 
for pts and 
decreases HCC. 
 
 
Application to 
Practice: 
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING 
Key: AE-Antiemetic; Adh- Adherence; An/v- Anticipatory nausea and vomiting; AP- Acute Phase; b/t- breakthrough; C1-Cycle one; 
C2- Cycle 2; C3-Cycle 3; C4-Cycle 4; Ca-Cancer; CINV- Chemotherapy induced nausea and vomiting; CR- Complete response; 
CT- Chemotherapy; d/t- due to; dex-dexamethasone; DP- delayed phase; DS- Descriptive Statistics; DV-dependent variable; ER-
Emergency Room; FACIT-Functional Assessment of Chronic Illness Therapy Fatigue; FACT-BR- Functional assessment of cancer 
therapy-brain; FLIE- Functional living index-emesis; f/u- follow up;  g/l-guideline;  GCP- guideline consistent prescribing; GEE- 
generalized equation estimates; GIC-guideline inconsistent prescribing; grp-group; HCC-Health Care Costs; HEC- Highly 
Emetogenic Chemotherapy; HP- Hospital Protocol; IG- Intervention group; inc-increase; Infn- Infusion; IV- independent variable;  
LEC- Low emetogenic chemotherapy; Lvl- level;  MASCC- Multinational Association of Supportive Care in Cancer; MAT-MASCC 
Antiemetic Tool; MEC- Moderately emetogenic chemotherapy; med- medication; N-number of studies; n- number of participants; 
n/v- nausea and/or vomiting; NCCN-National Comprehensive Cancer Network;  NK-1- Neurokinin receptor antagonist; outpt- 
outpatient; OV- Office visit; PC- physicians choice; Pt- Patient; Pts- Patients; QOL- quality of life; RF-Risk Factors; RMG-Risk 
model guided; Rx- Prescribing/prescription; std- Standard; VAS- visual analog scale; X2- Chi Squared 
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Country: 8 
European 
Countries 
 
Funding: 
Merck Sharp & 
Dohme Corp. 
 
Bias: None 
Stated. ESMO 
guideline study. 
 
GCP grp 
had less OV 
and ER visit 
follow tx 
 
Encourage GCP 
to decrease HCC 
and improve Pt 
outcomes.  
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING 
Key: AE-Antiemetic; Adh- Adherence; An/v- Anticipatory nausea and vomiting; AP- Acute Phase; b/t- breakthrough; C1-Cycle one; 
C2- Cycle 2; C3-Cycle 3; C4-Cycle 4; Ca-Cancer; CINV- Chemotherapy induced nausea and vomiting; CR- Complete response; 
CT- Chemotherapy; d/t- due to; dex-dexamethasone; DP- delayed phase; DS- Descriptive Statistics; DV-dependent variable; ER-
Emergency Room; FACIT-Functional Assessment of Chronic Illness Therapy Fatigue; FACT-BR- Functional assessment of cancer 
therapy-brain; FLIE- Functional living index-emesis; f/u- follow up;  g/l-guideline;  GCP- guideline consistent prescribing; GEE- 
generalized equation estimates; GIC-guideline inconsistent prescribing; grp-group; HCC-Health Care Costs; HEC- Highly 
Emetogenic Chemotherapy; HP- Hospital Protocol; IG- Intervention group; inc-increase; Infn- Infusion; IV- independent variable;  
LEC- Low emetogenic chemotherapy; Lvl- level;  MASCC- Multinational Association of Supportive Care in Cancer; MAT-MASCC 
Antiemetic Tool; MEC- Moderately emetogenic chemotherapy; med- medication; N-number of studies; n- number of participants; 
n/v- nausea and/or vomiting; NCCN-National Comprehensive Cancer Network;  NK-1- Neurokinin receptor antagonist; outpt- 
outpatient; OV- Office visit; PC- physicians choice; Pt- Patient; Pts- Patients; QOL- quality of life; RF-Risk Factors; RMG-Risk 
model guided; Rx- Prescribing/prescription; std- Standard; VAS- visual analog scale; X2- Chi Squared 
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Affronti et al. 
(2014). 
Adherence to 
antiemetic 
guideline in 
patients with 
malignant 
glioma: A quality 
improvement 
project to 
translate 
evidence into 
practice. 
 
Country: US 
(Duke 
University) 
 
Bias: None 
Stated.  
 
Change 
Theory 
Single arm 
quasi 
experimental 
study 
n= 61 pt 
order sets for 
MEC 
n= 32 pts 
surveyed for 
QOL 
 
Pts of 
providers 
who received 
intervention 
Chart Review of 
Rx 
 
Osoba Survey 
FACT-BR 
FACIT-fatigue 
 
DS 
Cronbach’s 
Alpha 
Wilcoxan 
Sign Rank 
test 
Post 
intervention 
adh 
increased 
from 58% to 
92% with 
edu and 
EMR; 
 
CR 75% 
with adh 
Lvl of evidence:  
Lvl 3 
 
Decision for 
Practice:  
g/l adh increases 
CR of CINV. 
 
 
Application to 
practice: 
Provider edu 
increase adh. 
 
Limitations: 
One center 
Specialty 
practice. 
Burmeister et al. 
(2012). 
Adherence to 
ESMO clinical 
recommendations 
 Retrospective 
observational  
n= 299 charts 
 
 
New CT pts 
 
Chart Review of 
Regimen 
DS 
Logistic 
Regression 
61% g/l adh 
 
Overuse of 
triple AE  
 
Lvl of Evidence: 
Lvl 3 
 
 
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING 
Key: AE-Antiemetic; Adh- Adherence; An/v- Anticipatory nausea and vomiting; AP- Acute Phase; b/t- breakthrough; C1-Cycle one; 
C2- Cycle 2; C3-Cycle 3; C4-Cycle 4; Ca-Cancer; CINV- Chemotherapy induced nausea and vomiting; CR- Complete response; 
CT- Chemotherapy; d/t- due to; dex-dexamethasone; DP- delayed phase; DS- Descriptive Statistics; DV-dependent variable; ER-
Emergency Room; FACIT-Functional Assessment of Chronic Illness Therapy Fatigue; FACT-BR- Functional assessment of cancer 
therapy-brain; FLIE- Functional living index-emesis; f/u- follow up;  g/l-guideline;  GCP- guideline consistent prescribing; GEE- 
generalized equation estimates; GIC-guideline inconsistent prescribing; grp-group; HCC-Health Care Costs; HEC- Highly 
Emetogenic Chemotherapy; HP- Hospital Protocol; IG- Intervention group; inc-increase; Infn- Infusion; IV- independent variable;  
LEC- Low emetogenic chemotherapy; Lvl- level;  MASCC- Multinational Association of Supportive Care in Cancer; MAT-MASCC 
Antiemetic Tool; MEC- Moderately emetogenic chemotherapy; med- medication; N-number of studies; n- number of participants; 
n/v- nausea and/or vomiting; NCCN-National Comprehensive Cancer Network;  NK-1- Neurokinin receptor antagonist; outpt- 
outpatient; OV- Office visit; PC- physicians choice; Pt- Patient; Pts- Patients; QOL- quality of life; RF-Risk Factors; RMG-Risk 
model guided; Rx- Prescribing/prescription; std- Standard; VAS- visual analog scale; X2- Chi Squared 
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for prophylaxis 
of chemotherapy-
induced nausea 
and vomiting 
 
Country: 
Switzerland 
 
Bias: None 
stated 
 
 
 
 
 
 
 
 
 
 
 
 
 
11% g/l adh 
in LEC 
No Dex DR 
with NK-1 
 
Decision for 
Practice: 
Over use of 
antiemetics 
reason for low g/l 
adh.  
 
Application to 
Practice: 
Provider edu on 
g/l… 
 
Limitations: 
Does not look at 
CINV CR 
outcomes.   
Does not include 
personal risk 
factors for low 
adh. 
 
 
Caracuel et al. 
(2015). 
Adherence to 
antiemetic 
guidelines and 
Medication 
adherence? 
Observational 
Study 
n= 102 Rx 
n= 10 Rx 
providers 
New CT pts Chart Review 
Daily Diary 
 
DS 
X2 
No sig 
between g/l 
adh and CR 
 
Lvl of Evidence: 
Lvl 3 
 
Decision for 
practice: 
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING 
Key: AE-Antiemetic; Adh- Adherence; An/v- Anticipatory nausea and vomiting; AP- Acute Phase; b/t- breakthrough; C1-Cycle one; 
C2- Cycle 2; C3-Cycle 3; C4-Cycle 4; Ca-Cancer; CINV- Chemotherapy induced nausea and vomiting; CR- Complete response; 
CT- Chemotherapy; d/t- due to; dex-dexamethasone; DP- delayed phase; DS- Descriptive Statistics; DV-dependent variable; ER-
Emergency Room; FACIT-Functional Assessment of Chronic Illness Therapy Fatigue; FACT-BR- Functional assessment of cancer 
therapy-brain; FLIE- Functional living index-emesis; f/u- follow up;  g/l-guideline;  GCP- guideline consistent prescribing; GEE- 
generalized equation estimates; GIC-guideline inconsistent prescribing; grp-group; HCC-Health Care Costs; HEC- Highly 
Emetogenic Chemotherapy; HP- Hospital Protocol; IG- Intervention group; inc-increase; Infn- Infusion; IV- independent variable;  
LEC- Low emetogenic chemotherapy; Lvl- level;  MASCC- Multinational Association of Supportive Care in Cancer; MAT-MASCC 
Antiemetic Tool; MEC- Moderately emetogenic chemotherapy; med- medication; N-number of studies; n- number of participants; 
n/v- nausea and/or vomiting; NCCN-National Comprehensive Cancer Network;  NK-1- Neurokinin receptor antagonist; outpt- 
outpatient; OV- Office visit; PC- physicians choice; Pt- Patient; Pts- Patients; QOL- quality of life; RF-Risk Factors; RMG-Risk 
model guided; Rx- Prescribing/prescription; std- Standard; VAS- visual analog scale; X2- Chi Squared 
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control of 
chemotherapy-
induced nausea 
and vomiting 
(CINV) in a large 
hospital.  
 
Country: Spain 
 
Bias:  
None Stated 
Adh to HP 
which was 
different the 
g/l 
Pt adh plays role 
in CINV and g/l 
adh 
 
Application for 
Practice: 
Need intervention 
to increase pt 
adherence. 
 
Limitations: 
Follow HP not std 
g/l.  
Chan et al. 
(2012). 
Assessment 
between 
adherence with 
antiemetic drug 
therapy and 
control of nausea 
and vomiting in 
breast cancer 
patients receiving 
anthracycline-
based 
chemotherapy. 
 
Physiological Prospective 
Observational 
study 
n=519 
 
123 excluded 
d/t loss of f/u 
or refused 
participation 
 
outpt clinic 
Cohort: 
Adult Breast 
Ca pts 
receiving 
anthracycline 
CT 
Diary 
Likert Scale for 
n/v 
f/u phone call 
 
DS 
X2 
Fisher’s 
exact test 
Linear 
association 
62% took b/t 
med 
57.9% adh 
to outpt med 
Low adh to 
dex Rx 
58.6% adh 
had CR in 
DP 
Lvl of Evidence:  
Lvl 3 
 
Decision for 
practice: g/l adh 
increases CR or 
CINV 
 
 
Application: 
Better adh 
decreases CINV. 
 
Limitations: 
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING 
Key: AE-Antiemetic; Adh- Adherence; An/v- Anticipatory nausea and vomiting; AP- Acute Phase; b/t- breakthrough; C1-Cycle one; 
C2- Cycle 2; C3-Cycle 3; C4-Cycle 4; Ca-Cancer; CINV- Chemotherapy induced nausea and vomiting; CR- Complete response; 
CT- Chemotherapy; d/t- due to; dex-dexamethasone; DP- delayed phase; DS- Descriptive Statistics; DV-dependent variable; ER-
Emergency Room; FACIT-Functional Assessment of Chronic Illness Therapy Fatigue; FACT-BR- Functional assessment of cancer 
therapy-brain; FLIE- Functional living index-emesis; f/u- follow up;  g/l-guideline;  GCP- guideline consistent prescribing; GEE- 
generalized equation estimates; GIC-guideline inconsistent prescribing; grp-group; HCC-Health Care Costs; HEC- Highly 
Emetogenic Chemotherapy; HP- Hospital Protocol; IG- Intervention group; inc-increase; Infn- Infusion; IV- independent variable;  
LEC- Low emetogenic chemotherapy; Lvl- level;  MASCC- Multinational Association of Supportive Care in Cancer; MAT-MASCC 
Antiemetic Tool; MEC- Moderately emetogenic chemotherapy; med- medication; N-number of studies; n- number of participants; 
n/v- nausea and/or vomiting; NCCN-National Comprehensive Cancer Network;  NK-1- Neurokinin receptor antagonist; outpt- 
outpatient; OV- Office visit; PC- physicians choice; Pt- Patient; Pts- Patients; QOL- quality of life; RF-Risk Factors; RMG-Risk 
model guided; Rx- Prescribing/prescription; std- Standard; VAS- visual analog scale; X2- Chi Squared 
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Country: 
Singapore 
 
Bias: None 
stated. 
NK-1 not used d/t 
cost. Used 
Independent g/l. 
Clemons et al. 
(2016). Risk 
Model guided 
antiemetic 
prophylaxis vs 
physcians choice 
in patients 
receiving 
chemotherapy for 
early-stage breast 
cancer: A 
randomized trial 
 
Country: 
Canada 
 
Funding: 
Canadian Breast 
Cancer Research 
Foundation 
 
Bias: None 
stated.  
Physiological RCT n= 324 
 
newly dx 
breast ca  
IV- RMG 
n=154 
DV- PC 
n=170 
 
RMG grp AE 
adjusted after 
each cycle 
FLIE index 
Likert scale 
f/u phone call 
DS 
Repeated 
measures 
6% in each 
grp An/v; 
4.1% in PC 
grp used 
NK-1; More 
med to inc 
control 
added to 
RMG grp 
than PC grp; 
Fewer pt in 
RMG 
required b/t 
med 
Lvl of Evidence: 
Lvl 2 
 
Decision for 
practice: 
Triple AE 
improve HEC 
CINV (g/l 
recommendation) 
 
Application: 
AE should be eval 
with each cycle of 
CT. 
 
Limitations: 
Did not use g/l 
but followed 
some 
recommendations. 
At one facility.  
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING 
Key: AE-Antiemetic; Adh- Adherence; An/v- Anticipatory nausea and vomiting; AP- Acute Phase; b/t- breakthrough; C1-Cycle one; 
C2- Cycle 2; C3-Cycle 3; C4-Cycle 4; Ca-Cancer; CINV- Chemotherapy induced nausea and vomiting; CR- Complete response; 
CT- Chemotherapy; d/t- due to; dex-dexamethasone; DP- delayed phase; DS- Descriptive Statistics; DV-dependent variable; ER-
Emergency Room; FACIT-Functional Assessment of Chronic Illness Therapy Fatigue; FACT-BR- Functional assessment of cancer 
therapy-brain; FLIE- Functional living index-emesis; f/u- follow up;  g/l-guideline;  GCP- guideline consistent prescribing; GEE- 
generalized equation estimates; GIC-guideline inconsistent prescribing; grp-group; HCC-Health Care Costs; HEC- Highly 
Emetogenic Chemotherapy; HP- Hospital Protocol; IG- Intervention group; inc-increase; Infn- Infusion; IV- independent variable;  
LEC- Low emetogenic chemotherapy; Lvl- level;  MASCC- Multinational Association of Supportive Care in Cancer; MAT-MASCC 
Antiemetic Tool; MEC- Moderately emetogenic chemotherapy; med- medication; N-number of studies; n- number of participants; 
n/v- nausea and/or vomiting; NCCN-National Comprehensive Cancer Network;  NK-1- Neurokinin receptor antagonist; outpt- 
outpatient; OV- Office visit; PC- physicians choice; Pt- Patient; Pts- Patients; QOL- quality of life; RF-Risk Factors; RMG-Risk 
model guided; Rx- Prescribing/prescription; std- Standard; VAS- visual analog scale; X2- Chi Squared 
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Dranitsaris et al. 
(2016). 
Measuring the 
impact of 
guideline-based 
antiemetic 
therapy on 
nausea and 
vomiting control 
in breast cancer 
patients with 
multiple risk 
factors. 
 
Country: 
Canada 
 
Funding: 
Canadian Breast 
Cancer Research 
Foundation 
 
Bias: None 
Stated. Same 
sample from 
Clemons et al.  
 
 Exploratory 
analysis 
n=152  
 
Newly dx 
breast Ca pt.  
 
(same sample 
as clemons et 
al.) 
Newly dx 
breast Ca pt 
in RMG 
utilizing 
personal RF 
FLIE index 
Diary 
Telephone call f/u 
 
Repeated 
Measures 
Pts with inc 
RF for 
CINV had 
higher 
instances of 
CINV 
despite 
prophylaxis.  
RMG 
decreased 
CINV from 
C1 to C4.  
Lvl of Evidence: 
Lvl 3 
 
Decision For 
Practice: 
Personal RF 
needs to be 
considered 
despite adequate 
prophylaxis. 
 
Application for 
practice: 
Consider personal 
RF for CINV 
when Rx for AE.  
 
Limitations: 
Missing data on 
3-6% of 
participants. 
Sample used in 
previous study. 
Don’t clearly 
identify g/l 
following.  
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING 
Key: AE-Antiemetic; Adh- Adherence; An/v- Anticipatory nausea and vomiting; AP- Acute Phase; b/t- breakthrough; C1-Cycle one; 
C2- Cycle 2; C3-Cycle 3; C4-Cycle 4; Ca-Cancer; CINV- Chemotherapy induced nausea and vomiting; CR- Complete response; 
CT- Chemotherapy; d/t- due to; dex-dexamethasone; DP- delayed phase; DS- Descriptive Statistics; DV-dependent variable; ER-
Emergency Room; FACIT-Functional Assessment of Chronic Illness Therapy Fatigue; FACT-BR- Functional assessment of cancer 
therapy-brain; FLIE- Functional living index-emesis; f/u- follow up;  g/l-guideline;  GCP- guideline consistent prescribing; GEE- 
generalized equation estimates; GIC-guideline inconsistent prescribing; grp-group; HCC-Health Care Costs; HEC- Highly 
Emetogenic Chemotherapy; HP- Hospital Protocol; IG- Intervention group; inc-increase; Infn- Infusion; IV- independent variable;  
LEC- Low emetogenic chemotherapy; Lvl- level;  MASCC- Multinational Association of Supportive Care in Cancer; MAT-MASCC 
Antiemetic Tool; MEC- Moderately emetogenic chemotherapy; med- medication; N-number of studies; n- number of participants; 
n/v- nausea and/or vomiting; NCCN-National Comprehensive Cancer Network;  NK-1- Neurokinin receptor antagonist; outpt- 
outpatient; OV- Office visit; PC- physicians choice; Pt- Patient; Pts- Patients; QOL- quality of life; RF-Risk Factors; RMG-Risk 
model guided; Rx- Prescribing/prescription; std- Standard; VAS- visual analog scale; X2- Chi Squared 
 
29 
Gilmore et al. 
(2014). 
Antiemetic 
guideline 
consistency and 
incidence of 
chemotherapy-
induced nausea 
and vomiting in 
US community 
practice: 
INSPIRE study. 
 
 Country: US 
 
Funding: 
Merck Sharp & 
Dohme Corp 
Physiological Prospective 
Observational 
Study 
n= 1295 
C1 new 
chemo for 
HEC or MEC 
per NCCN g/l 
IV- GCP 
n= 742 
DV-GIP 
n= 553 
MAT 
f/u phone call 
DS 
X2 
t-test 
Multivariate 
logistical 
regression 
Main reason 
for lack of 
g/l adh no 
dex Rx for 
DP. GCP 
had less 
CINV than 
GIP.  
Lvl of Evidence: 
Lvl 3 
 
Decision for 
Practice:  
GCP inc CR in 
CINV 
 
Application: g/l 
Rx to decrease 
CINV. 
 
Limitation: 
Assumed pts adh 
to home AE med. 
Research funded 
by pharmaceutical 
company. Data 
collected in one 
f/u phone call 5-8 
days after CT 
Inoue et al. 
(2015). Cohort 
study of 
consistency 
between the 
compliance with 
guidelines for 
Physiological  
Retrospective 
design 
n=73 
Outpt CT 
clinic  
CT pts in 
outpt setting 
monitored for 
g/l adh.  
MAT 
Chart Review 
DS  
Relative risk 
Inc g/l adh 
in AP, less 
g/l adh HEC 
in DP, 
CINV not 
prevented in 
22.2% in AP 
Lvl of Evidence: 
Lvl 3 
 
Decision for 
Practice: 
Evaluation of 
CINV and g/l adh 
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING 
Key: AE-Antiemetic; Adh- Adherence; An/v- Anticipatory nausea and vomiting; AP- Acute Phase; b/t- breakthrough; C1-Cycle one; 
C2- Cycle 2; C3-Cycle 3; C4-Cycle 4; Ca-Cancer; CINV- Chemotherapy induced nausea and vomiting; CR- Complete response; 
CT- Chemotherapy; d/t- due to; dex-dexamethasone; DP- delayed phase; DS- Descriptive Statistics; DV-dependent variable; ER-
Emergency Room; FACIT-Functional Assessment of Chronic Illness Therapy Fatigue; FACT-BR- Functional assessment of cancer 
therapy-brain; FLIE- Functional living index-emesis; f/u- follow up;  g/l-guideline;  GCP- guideline consistent prescribing; GEE- 
generalized equation estimates; GIC-guideline inconsistent prescribing; grp-group; HCC-Health Care Costs; HEC- Highly 
Emetogenic Chemotherapy; HP- Hospital Protocol; IG- Intervention group; inc-increase; Infn- Infusion; IV- independent variable;  
LEC- Low emetogenic chemotherapy; Lvl- level;  MASCC- Multinational Association of Supportive Care in Cancer; MAT-MASCC 
Antiemetic Tool; MEC- Moderately emetogenic chemotherapy; med- medication; N-number of studies; n- number of participants; 
n/v- nausea and/or vomiting; NCCN-National Comprehensive Cancer Network;  NK-1- Neurokinin receptor antagonist; outpt- 
outpatient; OV- Office visit; PC- physicians choice; Pt- Patient; Pts- Patients; QOL- quality of life; RF-Risk Factors; RMG-Risk 
model guided; Rx- Prescribing/prescription; std- Standard; VAS- visual analog scale; X2- Chi Squared 
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chemotherapy-
induced nausea 
and vomiting and 
patient outcome.  
 
Country: 
Japan 
 
Bias: None 
stated 
 
Application: 
Encourages use of 
g/l adherence in 
practice. 
 
 Limitations: 
Used 3 g/l in 
practice, used 
HEC, MEC, and 
LEC pts.  
 
Molassiotis et al. 
(2014). 
Evaluation of 
risk factors 
predicting 
chemotherapy 
related nausea 
and vomiting: 
Results from a 
European 
Prospective 
observational 
study.  
 
Physiological Prospective 
Observational 
Study 
n=1128 
137 excluded 
for no diary 
or CT change 
 
 
MASCC g/l 
n=991 CT 
naïve pts 
receiving 
HEC or MEC 
with GCP 
Diary  
VAS 
DS 
Multivariate 
Logistic 
Regression 
GEE 
Lack of CR 
from C1 to 
C2 
increased 
risk for 
CINV 6.6 
time; lack of 
CR in C2 
caused 8 
times inc in 
RF for 
CINV in C3.  
Lvl of Evidence: 
Lvl 3 
 
Decision for 
practice: 
g/l adh shows 
decreased rates of 
CINV but 
personal RF need 
to be considered 
Applications for 
Practice: 
An/v plays large 
role in CINV 
management. 
 
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING 
Key: AE-Antiemetic; Adh- Adherence; An/v- Anticipatory nausea and vomiting; AP- Acute Phase; b/t- breakthrough; C1-Cycle one; 
C2- Cycle 2; C3-Cycle 3; C4-Cycle 4; Ca-Cancer; CINV- Chemotherapy induced nausea and vomiting; CR- Complete response; 
CT- Chemotherapy; d/t- due to; dex-dexamethasone; DP- delayed phase; DS- Descriptive Statistics; DV-dependent variable; ER-
Emergency Room; FACIT-Functional Assessment of Chronic Illness Therapy Fatigue; FACT-BR- Functional assessment of cancer 
therapy-brain; FLIE- Functional living index-emesis; f/u- follow up;  g/l-guideline;  GCP- guideline consistent prescribing; GEE- 
generalized equation estimates; GIC-guideline inconsistent prescribing; grp-group; HCC-Health Care Costs; HEC- Highly 
Emetogenic Chemotherapy; HP- Hospital Protocol; IG- Intervention group; inc-increase; Infn- Infusion; IV- independent variable;  
LEC- Low emetogenic chemotherapy; Lvl- level;  MASCC- Multinational Association of Supportive Care in Cancer; MAT-MASCC 
Antiemetic Tool; MEC- Moderately emetogenic chemotherapy; med- medication; N-number of studies; n- number of participants; 
n/v- nausea and/or vomiting; NCCN-National Comprehensive Cancer Network;  NK-1- Neurokinin receptor antagonist; outpt- 
outpatient; OV- Office visit; PC- physicians choice; Pt- Patient; Pts- Patients; QOL- quality of life; RF-Risk Factors; RMG-Risk 
model guided; Rx- Prescribing/prescription; std- Standard; VAS- visual analog scale; X2- Chi Squared 
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Country: 8 
European 
Countries 
 
Funding:  
Merck Sharp & 
Dohme Corp 
 
Bias: 
Authors speakers 
and have 
received 
compensation 
from Merck 
Sharp & Dohme 
Corp. 
Limitations: 
Does not consider 
outpt adh as part 
of study.  
Citation Theory/ 
Conceptual 
Framework 
Design/ 
Method 
Sample/ 
Setting 
Major 
Variables 
& 
Definitions 
Measurement/ 
Instrumentation 
Data 
Analysis 
(stats 
used) 
Findings/ 
Results 
Level/Quality 
of Evidence; 
Decision for 
practice/ 
application to 
practice 
   N= 
n= 
IV- 
DV- 
    
 
CHEMOTHERAPY INDUCED NAUSEA AND VOMITING 
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Appendix C 
Synthesis Table 
 
 
Citation Guideline Tool Diary Phone Emetogenic 
Potential 
Emesis w/ g/l 
adherence 
Aapro et al. 
(2012) 
MASCC VAS; Precribing 
Inforomation 
X  HEC/MEC ¯ 
Affronti et al. 
(2014) 
MASCC/ESMO, 
NCCN, ASCO 
Chart Audit; 
Osoba 
  MEC ¯ 
Burmeister et al. 
(2012) 
MASCC/ESMO Chart Audt   HEC/MEC/LEC  
Caracuel et al. 
(2015) 
Indep/ASCO Chart Audit X  HEC/MEC/LEC/ Min « 
Chan et al. (2012). Independent Likert Scale X X HEC/MEC ¯ 
Clemons et al. 
(2016) 
ASCO FLIE index  X HEC/MEC ¯ 
Dranitsaris et al, 
(2016). 
ASCO FLIE index X X HEC/MEC ¯ 
Gilmore et al. 
(2014) 
NCCN MAT  X HEC/MEC ¯ 
Inoue et al. (2015) Independent MAT/Chart Audit   HEC/MEC/LEC/Min ¯ 
Molasiotis et al. 
(2014). 
MASCC VAS X  HEC/MEC ¯ 
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Appendix D 
Symptom Management Theory 
  
  
 
(Linder, 2010) 
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Appendix E 
Ottawa Model for Research Use
 
(Hogan & Logan, 2004) 
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Appendix F 
Pretest  
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Appendix G 
Posttest 
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